Research programme: esterase-sensitive motif targeted therapeutics - Macrophage Pharma

Drug Profile

Research programme: esterase-sensitive motif targeted therapeutics - Macrophage Pharma

Alternative Names: CHR 6155; MPL 5821

Latest Information Update: 20 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chroma Therapeutics
  • Developer Chroma Therapeutics; GlaxoSmithKline
  • Class Small molecules
  • Mechanism of Action DNA inhibitors; Histone deacetylase inhibitors; HSP90 heat-shock protein inhibitors; Macrophage colony stimulating factor inhibitors; P38 mitogen-activated protein kinase inhibitors; Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Inflammation

Most Recent Events

  • 11 May 2017 Macrophage Pharma plans a clinical trial in cancer
  • 20 Jan 2017 No development reported - Preclinical for Inflammation in United Kingdom (PO)
  • 09 Jan 2017 Esterase sensitive motif targeted therapeutics are still under preclinical development in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top